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Poly(ADP-ribose)polymerase-1 (PARP1) is a chromatin-associated enzyme that was described to
affect chromatin compaction. Previous reports suggested a dynamic modulation of the chromatin
landscape during adipocyte differentiation.We thus hypothesized that PARP1 plays an important
transcriptional role in adipogenesis and metabolism and therefore used adipocyte development
and function as a model to elucidate the molecular action of PARP1 in obesity-related diseases.
Our results show that PARP1-dependent ADP-ribose polymer (PAR) formation increases during
adipocyte development and, at late time points of adipogenesis, is involved in the sustained
expression of PPAR2 and of PPAR2 target genes. During adipogenesis, PARP1 was recruited to
PPAR2 target genes such as CD36 or aP2 in a PAR-dependent manner. Our results also reveal a
PAR-dependent decrease in repressory histone marks (e.g. H3K9me3) and an increase in stimula-
tory marks (e.g. H3K4me3) at the PPAR2 promoter, suggesting that PARP1 may exert its regula-
tory function during adipogenesis by altering histone marks. Interestingly, activation of PARP1
enzymatic activity was prevented with a topoisomerase II inhibitor. These data hint at topoisom-
erase II-dependent, transient, site-specific double-strand DNA breaks as the cause for poly(ADP)-
ribose formation, adipogenic gene expression, and adipocyte function. Together, our study identifies
PARP1 as a critical regulator of PPAR2-dependent gene expression with implications in adipocyte
function and obesity-related disease models. (Molecular Endocrinology 26: 79–86, 2012)
Obesity is a complex metabolic disorder characterizedby an excess of body fat that is closely associated
with other serious health conditions, such as heart disease
and diabetes. White adipose tissue, which is the predom-
inant type of fat in adult humans, serves as a storage depot
for excess energy. Adipose tissue secretes diverse adipo-
kines, such as leptin, Adiponectin, IL-6, TNF, and oth-
ers, that regulate blood pressure, immune function, and
energy balance (1, 2). Disturbed production of these fac-
tors may contribute to the development of insulin resis-
tance or impaired insulin secretion resulting in type 2
diabetes.
During adipogenesis, fibroblast-like preadipocytes dif-
ferentiate into lipid-laden and insulin-responsive adi-
pocytes, which requires a coordinate up-regulation of
many enzymes involved in fatty acid metabolism and
pyridine nucleotides as coenzymes (3). The murine
3T3-L1 cell line (4) has been broadly used as a model
system to study adipogenesis. 3T3-L1 cells undergo a syn-
chronous differentiation process upon addition of an adi-
pogenic cocktail and have been influential for the under-
standing of the complex regulatory networks during
adipogenesis. Adipocyte differentiation is accompanied
by large-scale chromatin changes and by the establish-
ment of transcription factor “hotspots” (5). This process
occurs in several stages and involves a cascade of tran-
scription factors, among which the CCAAT/enhancer-
binding proteins (C/EBP) C/EBP- and C/EBP- are
considered crucial determinants for the expression of
the key factor peroxisome proliferator-activated receptor
 (PPAR) and of C/EBP- (6, 7). A positive feedback
loop between PPAR and C/EBP- mutually regulates
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their expression, and together, these two proteins coordi-
nate adipocyte function (7, 8). In contrast to PPAR1,
PPAR2 expression is mainly restricted to adipocytes (9).
PPAR2, together with several coactivators, regulates an
array of target genes, ofwhich aP2,CD36, andAdiponec-
tin have crucial roles for adipocyte function by regulating
fatty acid binding, translocation, and catabolism, respec-
tively (5). Deletion of PPAR2 in mouse adipose tissues
protects against high-fat diet-induced obesity and insulin
resistance, but these mice display increased lipid deposi-
tion in muscle and liver (10). Similarly, ablation of
PPAR2 in mice of the ob/ob background results in de-
creased fat mass, severe insulin resistance, -cell failure,
and dyslipidemia (11).
Poly(ADP-ribose)polymerase-1 (PARP1) (recently re-
named ADP-ribosyltransferase diphtheria toxin-like 1)
(12) is an abundant, ubiquitous chromatin-associated
enzyme that catalyzes the nicotinamide adenine dinucle-
otide (NAD)-dependent addition of polymers of ADP-
ribose (PAR) onto a variety of target proteins (13). PAR is
a large, negatively charged polymer that functions as
posttranslational protein modification. Most PAR in the
cell is produced by the catalytic activity of PARP1,
which is the main ADP-ribosyltransferase in the nu-
cleus (14). In vitro, PARP1 enzymatic activity is strongly
activated upon binding to various interaction partners,
such as nucleosomes or certain forms of DNA (15). In
vivo, polymer formation by PARP1 is undetectable by
immunofluorescence under basal (unstimulated) condi-
tions but can be detected upon treatment of cells with
DNA-damaging compounds (13). Lack of PARP1 in
cells was reported to affect the gene expression profile
in a genome-wide manner (15). Besides restructuring
the chromatin and influencing transcription indirectly
(16, 17), PARP1 can additionally act as a transcrip-
tional cofactor during transcription by directly inter-
acting with a variety of transcription factors (18).
Previous studies reported the body weight of adult
PARP1/ mice in diverse genetic backgrounds to be
different than the corresponding controls (19, 20). Here,
we extend these studies to the molecular level and show
with different experimental approaches that PARP1-
dependent PAR formation increases during adipocyte de-
velopment and is involved in regulating adipocyte devel-
opment and function.
Results
ADP-ribosylation is required for sustained
PPAR2-dependent gene expression
To investigate whether PARP1 and its enzymatic ac-
tivity have an effect on adipogenesis, 3T3-L1 preadi-
pocytes were differentiated into adipocytes by addition of
an adipogenic cocktail (21). Western blot analysis from
the differentiated 3T3-L1 cell extracts revealed a shift of
PARP1 at d 7, suggesting auto-ADP-ribosylation of
PARP1 (Fig. 1A). Further Western blot analysis using an
antibody against the PAR confirmed that PAR formation
was indeed activated after d 3 of adipocyte differentia-
tion. Moreover, PAR formation was strongly reduced in
differentiating 3T3-L1 cells that were treated with the
PARP inhibitor PJ34 (or Olaparib, data not shown), pro-
viding further evidence that ADP-ribosylation was indeed
induced in 3T3-L1 extracts (Fig. 1A). A detailed kinetic
analysis detected PAR formation already at d 4 after
induction of adipocyte differentiation, which remained
elevated until d 10 (Supplemental Fig. 1A, published on
The Endocrine Society’s Journals Online web site at
http://mend.endojournals.org).
Interestingly, PJ34 treatment also inhibited storage of
free fatty acids in the adipocytes as judged by Oil-Red O
staining (Fig. 1B and Supplemental Fig. 1B), suggesting
that adipocyte function might require PAR formation.
Next, we evaluated the functional contribution of PAR
formation for the transcriptional activation of the main
FIG. 1. PAR formation is important during adipogenesis. 3T3-L1
preadipocytes were subjected to adipocyte differentiation during 7 d in
the absence or presence of PARP inhibitor PJ34 (10 M). Inhibitor was
supplemented daily. A, Total-cell extracts were prepared and analyzed
by Western blotting. An experiment done in duplicates is shown. B,
Cells were stained with Oil-Red O, bound Oil-Red O was extracted, and
quantified colorimetrically. Result show the mean  SEM, n  3.
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drivers of adipogenesis by quantitative PCR. The expres-
sion of C/EBP-, the main transcriptional regulator of
initial PPAR2 expression, as well as of C/EBP- and
PPAR2, was significantly induced upon initiation of ad-
ipogenesis and not affected by the PARP inhibitor PJ34
(at d 3) (Fig. 2A). In contrast, although the sustained
expression level of C/EBP- at d 7 was not affected by
PARP inhibition, the C/EBP- and PPAR2 mRNA lev-
els at this later time point were significantly reduced by
the presence of PJ34 for 6 d (Fig. 2A). The reduction in
PPAR2 mRNA levels was also mani-
fested in PPAR2 protein levels, al-
though a residual amount of PPAR2
was still observed after 6 d of PJ34
treatment (Fig. 2B). Thus, the sus-
tained expression (after d 3 of adipo-
genesis) of C/EBP- and PPAR2 re-
quires the formation and presence of
PAR. To elucidate whether the expres-
sion of PPAR2 target genes might
consequently also be affected by ADP-
ribosylation, we analyzed the expres-
sion of aP2, CD36, and Adiponectin.
AlthoughaP2 expressionwasdetectedat
d 3 and then increased substantially until
the late phase of adipogenesis (d 7),
CD36 or Adiponectinwere significantly
expressed only at d 7 (Fig. 2C). Remark-
ably, the expression of all three genes
was abrogated by the PARP inhibitor
PJ34 (Fig. 2C), suggesting that PPAR2-
dependent gene expression is indeed reg-
ulated by PAR formation.
To investigate whether known hi-
stone modifications (22, 23) were af-
fected by PJ34 treatment, repressory
(H3K9me3) and stimulatory marks
(H3K4me3) were assessed at the
PPAR2 promoter. Chromatin im-
munoprecipitation (ChIP) experiments
revealed that the repressory histone
mark H3K9me3 decreased during dif-
ferentiation (d 7), whereas PJ34 treat-
ment blocked the release of this repres-
sory histone mark at the PPAR2
promoter (Fig. 2D). In contrast, the
stimulatory histone mark H3K4me3
increased at the same promoter during
adipocyte differentiation (d 7), and
PJ34 treatment blocked its accumula-
tion, which is in agreement with the
effects that were observed at the gene
expression level (Fig. 2D).
3T3-L1 adipocyte differentiation is inhibited by
PARP1 depletion
To further assess a specific involvement of PARP1 (but
not other PARP family members) and its enzymatic activ-
ity in PPAR2-dependent gene expression, undifferenti-
ated 3T3-L1 preadipocytes were transduced with a lenti-
virus expressing short hairpin RNA (shRNA) against
PARP1 (to stably knockdown PARP1) or a scrambled
FIG. 2. PAR formation is required for sustained PPAR2-dependent gene expression. 3T3-L1
preadipocytes were subjected to adipocyte differentiation for 7 d in the absence or presence
of PARP inhibitor PJ34 (10 M). Inhibitor was supplemented daily. A, Real-time RT-PCR
analysis for C/EBP-, C/EBP-, and PPAR2 is shown. mRNA levels were normalized with
Cyclophilin A. Results show the mean  SEM, n  3. ns, P  0.05; *, P  0.05; **, P  001.
B, Total-cell extracts were prepared and analyzed by Western blotting. C, Relative expression
levels of the PPAR2-dependent genes CD36, aP2, and Adiponectin were determined as in A.
D, ChIP analysis with H3K9me3 and H3K4me3 antibodies on the PPAR2 promoter. The
experiment was performed twice with similar results, and one experiment is shown.
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control RNA (Fig. 3, A and B). As compared to uninfected
cells, PARP1 mRNA levels decreased slightly in mock-
treated cells, whereas in shPARP1 3T3-L1 cells, PARP1
mRNA and protein expression were below 1% of the
levels observed in shmock cells (Fig. 3, A and B). Further-
more, no PAR formation was detected in the extracts of
differentiated shPARP1 cells (Fig. 3C), suggesting that the
observed PAR formation during adipogenesis was indeed
dependent on PARP1. Next, we investigated whether de-
pletion of PARP1 affects adipocyte differentiation. As
judged by Oil-Red O staining, cells efficiently depleted of
PARP1 were strongly hampered in their development to
mature adipocytes (Fig. 3D). Moreover, the expression of
PPAR2 itself and the expression of PPAR2 target genes
such as aP2 and Adiponectin was strongly reduced after
7 d of induced differentiation in shPARP1 3T3-L1 cells
(Fig. 3E). These results suggest that PARP1 and PARP1-
induced PAR formation are required for PPAR2 expres-
sion and subsequent adipocyte differentiation and that
other PARP family members cannot
compensate for the lack of PARP1 dur-
ing adipocyte differentiation.
Topoisomerase II inhibitor
merbarone inhibits PAR
formation and PPAR2-dependent
gene expression
Activation of PARP1 and subsequent
induction of transcription can be caused
by topoisomerase II-mediated, transient,
site-specific DNA double-strand breaks
(24).We therefore sought to testwhether
the upstream event that activates PARP1
enzymatic activity requires topoisomer-
ase II-dependent double-strand DNA
break formation. To investigate this pos-
sibility, 3T3-L1 cells were treated during
the last 2 or 3 d of differentiation (treat-
ment at d 5–6 or 4–6, respectively) with
PARP inhibitor (PJ34) or topoisomerase
II inhibitor (merbarone). PJ34 efficiently
inhibited PAR formation even when
added only in the later stages of differenti-
ation (d 5 and 6) (Fig. 4A) and could still
strongly affect PPAR2-dependent gene
expression, whereas PPAR2, once ex-
pressed, was minimally changed (Fig. 4B
and Supplemental Fig. 2, A and B). Inter-
estingly,merbarone also reducedPAR for-
mation significantly, indicating that topo-
isomerase II activity may be at least partly
responsible for PARP1 activation.
In addition, the expression of
PPAR2, aP2, Adiponectin, and CD36 was strongly re-
duced in cells treated withmerbarone during d 5 and 6 (Fig.
4C). To rule out that merbarone directly inhibits PARP1
enzymatic activity, we performed in vitro auto-ribosylation
assays (Supplemental Fig. 2C). Although PJ34 efficiently
blocked PAR formation,merbarone did not have an in vitro
inhibitory effect on PAR formation, even at concentrations
as high as 80 M (Supplemental Fig. 2C). These results
suggest that topoisomerase II is responsible for the
observed activation of PARP1 during the later phase of
adipogenesis. Unfortunately, we were not able to dem-
onstrate recruitment of topoisomerase II to the CD36
and aP2 promoters in adipocytes with the available
antibodies.
PAR formation enhances PARP1
chromatin recruitment
To further address the direct functional link between
PARP1 and PAR formation for PPAR2-dependent gene
FIG. 3. Depletion of PARP1 retards 3T3-L1 differentiation into adipocytes. Knockdown of
PARP1 was confirmed by (A) Western blot and (B) quantitative-PCR analyses. C, shmock or
shPARP1 3T3-L1 preadipocytes were differentiated into adipocytes for 7 d. Western blot
analysis with total-cell extracts shows PARP1 and PAR levels in shmock and shPARP1 cells
during adipogenesis (d 0, 3, and 7 of differentiation). D, Oil-Red O staining of shmock and
shPARP1 cultures that were subjected to 7 d of adipocyte differentiation. E, Real-time RT-PCR
analysis of PPAR2, aP2, and Adiponectin in shmock and shPARP1 cells after 7 d of adipocyte
differentiation. mRNA levels were normalized with Cyclophilin A. Results show the mean 
SEM, n  3.
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expression, we investigated the recruitment of PARP1 to
PPAR2 target promoters by ChIP. ChIP analysis re-
vealed that PARP1 was already present at the CD36 and
aP2 promoters in undifferentiated cells, but this associa-
tion was substantially increased at d 7 (Fig. 4D). Interest-
ingly, PARP1 recruitment was abrogated when the cells
were treated either with PJ34 or withmerbarone, suggest-
ing that the association of PARP1with the tested promot-
ers was dependent on PAR formation, which is induced
by topoisomerase II activity.
Discussion
In this study, we provide evidence that PARP1 controls
adipocyte function in vitro. Our results show that PARP1
is activated after the initial phase of adipogenesis and that
either depletion of PARP1 or inhibition of ADP-ribosyla-
tion strongly retard the functional dif-
ferentiation of 3T3-L1 cells. These
findings are in agreement with earlier
results showing that PAR formation
during adipogenesis is increased, al-
though an initial decrease at the begin-
ning of adipocyte differentiation was
observed (25). Furthermore, inhibition
of topoisomerase II strongly reduced
PARP1 activation and adipocyte
function.
Recent genome-wide analyses re-
vealed a dramatic and dynamic modula-
tion of the chromatin landscape during
the first hours of adipocyte differentia-
tion that coincides with cooperative
binding of multiple early transcription
factors (including glucocorticoid recep-
tor, retinoid X receptor, Stat5a, C/EBP-
, and C/EBP-) to transcription factor
hotspots (5). C/EBP- marks a large
number of these transcription factor hot-
spots before induction of differentiation
and chromatin remodeling and is re-
quired for their establishment. Because
the expression of C/EBP- was inde-
pendent of PAR formation during the
whole differentiation period (Fig. 2A),
our experiments suggest that PAR for-
mation is not required for the forma-
tion of the transcription factor hot-
spots. In contrast, although the initial
induced gene expression of PPAR2
and C/EBP- (at d 3) was not affected
by PJ34 treatment, the sustained ex-
pression of both genes was reduced upon inhibition of
PAR formation. Therefore, PAR appears to be necessary
for the positive feedback loop that brings about the mu-
tual stimulation of PPAR2 and C/EBP- expression.
Sustained PPAR2-dependent gene expression was abro-
gated even after inhibition of PAR formation only for the
last 2 d (d 5 and 6), whereas PPAR2 protein levels were
affected minimally (Fig. 4B). These results provide con-
vincing evidence that the induction of PAR formation and
its maintenance are important for sustained PPAR2-
dependent gene expression and adipocyte function.
Moreover, this indicates that the reduced PPAR2 target
gene expression is not caused by a lack of cellular
PPAR2 but likely due to an additional function of PAR
in PPAR2-dependent gene expression. Even though the
genetic experiments and inhibitor studies demonstrate a
strong correlation between PAR formation and adipo-
FIG. 4. PAR formation is dependent on topoisomerase II activity and required for PARP1
chromatin recruitment. A, 3T3-L1 preadipocytes were differentiated for 7 d. At d 4–6 or 5–6,
10 M PJ34 or 40 M merbarone was added to the medium. Total-cell extracts were prepared
and analyzed by Western blotting. B, 3T3-L1 preadipocytes were subjected to adipocyte
differentiation. 10 M PJ34 was supplemented at d 5 and 6. Total-cell extracts from the
indicated days were analyzed for PPAR2 protein expression. C, Real-time RT-PCR analysis on
d 7 from differentiated 3T3-L1 cells that were treated at d 5 and 6 of differentiation with
dimethyl sulfoxide control or 40 M merbarone. mRNA levels were normalized with
Cyclophilin A. Results are from three independent experiments, mean  SEM. D, ChIP analysis
with the PARP1 antibody on CD36 and aP2 promoter. Negative control (beads from d 0
samples) was set as 1. Results are from five independent experiments, mean  SEM.
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genic gene expression, additional off-target effects of the
PJ34 inhibitor cannot be excluded (e.g. on other NAD
consuming enzymes). However, given that most of the
observed PAR formation at d 7 was associated with
PARP1 and that PARP1 knockdown hampered adipo-
genesis, it is very likely that PARP1 enzymatic activity
is required for this process, although we can currently
not completely rule out that other ADP-ribosyltrans-
ferases, such as PARP2, also contribute to the observed
effect (26).
PAR formation by PARP1 could affect adipogenesis in
multiple ways: 1) by excluding or retaining transcription
factors from a special chromatin site (7); 2) by dissociat-
ing corepressors that occupy PPAR2 and PPAR2 target
promoters during adipocyte differentiation, allowing the
recruitment of transcription coactivators; and finally 3)
by regulating histone modifying enzymes and subse-
quently altering histone modifications (27).
Along this line, mechanistically, our data implicate
that topoisomerase II-induced DNA strand breaks as an
upstream event preceding PAR formation, whereas al-
tered histone modifications may represent the down-
stream effect of PARP1 activation. The reduced H3K4
trimethylation (Fig. 2D) upon PJ34 treatment is in agree-
ment with the finding that PARP1 prevents H3K4me3
demethylation (27). In addition, our data further suggest
an effect of PARP1 on the H3K9me3 modification (Fig.
2D). PAR could affect H3 marks either via histone
demethylases (e.g. lysine demethylases) or through spe-
cific methyltransferases (e.g. EHMT1/2, GLP, SETDB1,
or Suv39h1). Consequently, PAR formation may cause a
shift from repressory to activatory histone marks and
thereby affect adipogenesis. PARP1 itself is activated by
DNA damage, which could be brought about by topo-
isomerase II activity. Topoisomerase II cuts DNA strands
during replication (separation of DNA supercoils). How-
ever, the later stages of adipocyte differentiation are ac-
companied by an exit from the cell cycle (28), thereby
excluding this replication-dependent phenomenon as an
explanation for the regulation by topoisomerase II. The
induction of PARP1 by topoisomerase II in differentiating
adipocytes is therefore likely to be mediated by a tran-
sient, site-specific double-strand DNA break at the pro-
moters of PPAR2-dependent target genes, as described
for nuclear receptors (29).
PARP1 recruitment to the promoters of different
PPAR-dependent target genes was strongly enhanced
upon PAR formation. This observation is in contrast to
earlier in vitro studies, suggesting that automodified
PARP1 is released from chromatin (17) or that PJ34 treat-
ment does not affect PARP1 binding to target gene pro-
moters (27). However, in Drosophila, the presence and
activity of PARP1 is also required tomaintain a transcrip-
tion compartment by retaining transcription factors (30),
which also suggests a function for PARP1 enzyme activity
at the promoters of active genes as our findings in this
study.
The cellular PAR levels are determined by the synthe-
sizing activities of PARP and the degradation by poly-
(ADP-ribose)glycohydrolase, the main cellular enzyme
required for PAR degradation. The fact that PAR levels
were reduced upon the inhibition of PARP1 shortly be-
fore the extraction (data not shown) suggests that these
PAR polymers are not stable but rather constantly formed
and degraded. Consequently, the strong PAR formation
during adipocyte differentiation (as compared with the
PAR formation as a response to genotoxic stress such as
H2O2 treatment) must be due to constant synthesis,
which has been documented for the late stages of adipo-
genesis (25). However, activation of ADP-ribosyltrans-
ferases and of PAR formation can drastically affect cellu-
lar metabolite levels, such as NAD, nicotinamide
adenine dinucleotide phosphate, ATP, or glucose-6-phos-
phate and thereby even indirectly impair cell viability
(31). Interestingly, NAD levels during adipogenesis
were slightly elevated (Supplemental Fig. 3) or even dras-
tically increased during adipocyte differentiation of
3T3-L1 cells as described by others (3). This explains why
the differentiated cells are not dying upon extensive PAR
formation (due to the extended NAD and subsequent
ATP depletion) as suggested earlier (32). Thus, high
NAD levels may maintain PAR formation due to in-
creased substrate availability in a DNA damage-indepen-
dent manner. In summary, these data suggest that in-
creased NAD synthesis fuels the substantial PAR
synthesis and thus allows a constant PAR turnover during
adipogenesis.
In conclusion, our data reveal a novel metabolic func-
tion of PARP1 in adipose tissue and provide evidence that
PARP1 and topoisomerase II regulate the adipogenic gene
expression program. These observations additionally
provide insight into the link between cellular metabolism
(e.g. production of NAD), gene expression, and differ-
entiation. It will be interesting to investigate whether the
inhibition of ADP-ribose formation by PARP inhibitors
affects the pathological conditions, such as metabolic
disorders.
Materials and Methods
3T3-L1 cell culture and differentiation
3T3-L1 preadipocytes were cultured in DMEM containing
10% (vol/vol) fetal calf serum. On d 2 (2 d after 3T3-L1 prea-
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dipocytes reached confluence), cells were induced to differenti-
ate by insulin (5 g/ml), 3-isobutyl-1-methylxanthine (0.5
mmol/liter), and dexamethasone (1 mol/liter). On d 4, regular
DMEM containing insulin (5 g/ml) was substituted until d 7.
Cells were differentiated in the presence or absence of PJ34 (10
M), which was supplemented to cells every 24 h. Differentia-
tion was monitored by morphological assessment and Oil-Red
O staining. For Oil-Red O staining, cells were washed twice
with PBS, fixed in 10% formaldehyde for 1 h, and stained for 10
min with 0.2% (wt/vol) Oil-Red O solution in 60% (vol/vol)
isopropanol. Cells were then washed several times with water,
and excess water was evaporated by placing the stained cultures
at approximately 32 C. For the quantification of the staining,
the Oil-Red O was extracted with 100% isopropanol from the
cells and measured at 500 nm.
Reagents
Dexamethasone (D-4902), 3-isobutyl-1-methylxanthine (I-
5879), insulin (I-9278), Oil-Red O (00625), and merbarone
(M2070) were obtained from Sigma-Aldrich (St. Louis, MO).
Anti-PARP (sc-7150) antibody was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA), anti-PAR (51-8114KC)
from BD Pharmingen (San Diego, CA), anti-H3 (1791-100)
from Abcam (Cambridge, MA), anti-H3K9me3 (07-442) from
Millipore (Bedford, MA), anti-H3K4me3 (07-473) from Milli-
pore, and antitubulin (T6199) antibody from Sigma-Aldrich.
PJ34 was purchased from Alexis Biochemicals (San Diego, CA)
(ALX-270-289-0000).
Whole-cell extraction
Whole-cell extracts were prepared by lysing the cells for 20
min in radioimmunoprecipitation assay buffer [50 mM Tris (pH
8), 400mMNaCl, 0.5%Nonidet P-40, 1% deoxycholate, 0.1%
sodium dodecyl sulfate, 1 g/ml pepstatin, 1 g/ml bestatin, 2
g/ml leupeptin, 2 mM phenylmethylsulfony lfluoride, 10 mM
-glycerophosphate, 1 mMNaF, and 1mM dithiothreitol] at 4 C
rotating on the wheels. Lysate was centrifuged for 20 min at 4 C
at 14,000 rpm. Total proteins were loaded on 7.5% sodium
dodecyl sulfate gels and blottedwith anti-PAR, anti-PARP, anti-
PPAR, and antitubulin antibodies.
In vitro ADP-ribosylation assay
ADP-ribosylation assays were performed as earlier de-
scribed (33). Briefly, 400 nM PARP1 was incubated with 100
nM 32P-NAD and 200 nM DNA in PARP reaction buffer in
the presence or absence of PJ34 (20 M) or merbarone (20,
60, or 80 M).
NAD measurements
For NADmeasurements, 0.5 106 cells of differentiated
or undifferentiated 3T3-L1 cells were pelleted, and total NAD
was measured using the EnzyChrom NAD/NADH Assay kit
(E2ND-100) from BioAssay Systems (Hayward, CA) according
to the manufacturers’ instructions.
RNA extraction and real-time PCR analysis
Total RNA from 3T3-L1 cells was extracted using TRIzol
(Invitrogen, Carlsbad, CA) with a deoxyribonuclease step.
Equal amount of RNAwere reverse transcribed using the High-
Capacity cDNAReverse Transcription kit (Applied Biosystems,
Foster City, CA). Real-time PCR was performed using the Ro-
tor-Gene 3000 (Corbett Life Science, now QIAGEN, Valencia,
CA).Cyclophilinwas chosen as the internal control for normal-
ization after screening several candidate genes.
Chromatin immunoprecipitation
ChIP experiments were performed as described earlier (34).
Stable PARP1 knockdown in 3T3-L1 cells
Generation of viruses and transduction of cells was done as
described earlier (35). Briefly, pRDI vector expressing PARP1
shRNA was used to transduce 3T3-L1 cells. The shRNA was
directed against the sequence encoding the catalytic region of
PARP1, which was amplified with the following primers:
5-GATCCCCAAGAGCGACGCTTATTACTGTTTCAAGA-
GAACAGTAATAAGCGTCGCTCTTTTTTTGGAAA-3 (sense)
and 5-AGCTTTTCCAAAAAAAGAGCGACGCTTATTACTG-
TTCTCTTGAAACAGTAATAAGCGTCGCTCTTGGG-3 (anti-
sense). Transduced cells were selected through puromycin-resis-
tance gene.
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